An Update on the Clinical Pipelines of New Antibacterial Drugs Developed in China
Xinyi Yang(University of Sussex), Xuefu You(Chinese Academy of Medical Sciences & Peking Union Medical College), Birgitta Henriques‐Normark(Karolinska Institutet), Xiukun Wang(Chinese Academy of Medical Sciences & Peking Union Medical College), Staffan Normark(Karolinska University Hospital), Zhonghui Zheng(Luye Pharma (China)), Jian‐Dong Jiang(Chinese Academy of Medical Sciences & Peking Union Medical College), Luni Chen(Karolinska Institutet), Peiyi Sun(Hong Kong Polytechnic University), Chunjie Xu(Hefei University of Technology), Congran Li(Chinese Academy of Medical Sciences & Peking Union Medical College)
Cited by 12
Related Papers
Changes in the incidence of invasive disease due to Streptococcus pneumoniae, Haemophilus influenzae, and Neisseria meningitidis during the COVID-19 pandemic in 26 countries and territories in the Invasive Respiratory Infection Surveillance Initiative: a prospective analysis of surveillance data
|The Lancet Digital Health|2021|536
Discovery of a novel class of highly conserved vaccine antigens using genomic scale antigenic fingerprinting of pneumococcus with human antibodies
|The Journal of Experimental Medicine|2007|271
AmpD, essential for both β‐lactamase regulation and cell wall recycling, is a novel cytosolic <i>N</i>‐acetylmuramyl‐L‐alanine amidase
|Molecular Microbiology|1995|201
Trends in invasive bacterial diseases during the first 2 years of the COVID-19 pandemic: analyses of prospective surveillance data from 30 countries and territories in the IRIS Consortium
|The Lancet Digital Health|2023|157
Research progress of the defects and innovations of ceramic vat photopolymerization
|Additive manufacturing|2023|108